{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:14:54Z","timestamp":1779930894295,"version":"3.53.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtm.2024.101344","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:58:23Z","timestamp":1726934303000},"page":"101344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics"],"prefix":"10.1016","volume":"32","author":[{"given":"Rudolf W.","family":"van Olden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lo Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Dilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Savelieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloys","family":"Tijsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel","family":"van Baalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Mumneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101344_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2024.101344_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101344_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"10.1016\/j.omtm.2024.101344_bib4","series-title":"Spinal Muscular Atrophy","author":"Prior","year":"2000"},{"key":"10.1016\/j.omtm.2024.101344_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101344_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101344_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cpt.2247","article-title":"Prognostic factors and treatment-effect modifiers in spinal muscular atrophy","volume":"110","author":"Baranello","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtm.2024.101344_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2020.00555","article-title":"Vertically transferred immunity in neonates: mothers, mechanisms and mediators","volume":"11","author":"Albrecht","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101344_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fimmu.2014.00446","article-title":"Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies","volume":"5","author":"Niewiesk","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101344_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101344_bib11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101344_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101117","article-title":"Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy","volume":"31","author":"Day","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101344_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.omtm.2024.101344_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2024.101344_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101344_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2024.101344_bib17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101344_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101344_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2024.101344_bib20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101344_bib21","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.omtm.2024.101344_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41434-022-00339-0","article-title":"Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screening for treatment with onasemnogene abeparvovec\u00a0\u2013 routine care evidence","volume":"30","author":"Aharoni","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101344_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2024.101344_bib24","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.vaccine.2020.12.049","article-title":"Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies","volume":"40","author":"Albrecht","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2024.101344_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.vaccine.2021.12.007","article-title":"The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis","volume":"40","author":"Oguti","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2024.101344_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101344_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JND-221659","article-title":"Repeated AAV9 titer determination in a presymptomatic SMA patient with three SMN2 gene copies - a case report","volume":"11","author":"Eisenk\u00f6lbl","year":"2024","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2024.101344_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ijns10020038","article-title":"Current status of newborn bloodspot screening worldwide 2024: a comprehensive review of recent activities (2020\u20132023)","volume":"10","author":"Therrell","year":"2024","journal-title":"Int. J. Neonatal Screen."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:05:39Z","timestamp":1737666339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2329050124001608"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101344","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101344"}}